Sec Form 13D Filing - 5AM Ventures IV L.P. filing for IDEAYA BIOSCIENCES INC (IDYA) - 2020-12-14

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13D

 

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

TO RULE 13d-2(a)

 

(Amendment No. 2)*

 

IDEAYA Biosciences, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

45166A 102

(CUSIP Number)

 

Rebecca Lucia

5AM Venture Management, LLC

501 2nd Street, Suite 350

San Francisco, CA 94107

(415) 993-8565

 

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

December 10, 2020

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

 


* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

 

 


 

CUSIP No. 45166A 102

13D

 

 

1.

Name of Reporting Persons

 

5AM Ventures IV, L.P.

2.

Check the Appropriate Box if a Member of a Group (see instructions)

 

 

(a)

o

 

(b)

x(1)

3.

SEC USE ONLY

4.

Source of Funds (see instructions)

 

WC

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

o

6.

Citizenship or Place of Organization


Delaware, United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

1,477,028 shares of common stock (2)

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

1,477,028 shares of common stock (2)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,477,028 shares of common stock (2)

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

o

13.

Percent of Class Represented by Amount in Row 11

5.1% (3)

14.

Type of Reporting Person (see instructions)

 

PN

 


(1) This Schedule 13D is filed by 5AM Partners IV, LLC (“5AM Partners IV”), 5AM Ventures IV, L.P. (“5AM IV”),  5AM Co-Investors IV, L.P. (“5AM Co-Investors IV”), 5AM Opportunities I, L.P. (“5AM Opportunities”), 5AM Opportunities I (GP), LLC (“5AM Opportunities GP”), Dr. John D. Diekman (“Diekman”), Andrew J. Schwab (“Schwab”) and Dr. Scott M. Rocklage (“Rocklage” and, with 5AM Partners IV, 5AM IV, 5AM Co-Investors IV, 5AM Opportunities, 5AM Opportunities GP, Diekman and Schwab, collectively, the “Reporting Persons”).  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) These shares are held by 5AM IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV.

(3) This calculation is based on  29,069,719 shares of Common Stock, par value $0.0001 per share, outstanding as of November 6, 2020, as reported in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2020 (the “10-Q”) filed on November 12, 2020 with the Securities and Exchange Commission (the “SEC”).

 

2


 

CUSIP No. 45166A 102

13D

 

 

1.

Name of Reporting Persons

 

5AM Co-Investors IV, L.P.

2.

Check the Appropriate Box if a Member of a Group (see instructions)

 

 

(a)

o

 

(b)

x(1)

3.

SEC USE ONLY

4.

Source of Funds (see instructions)

 

WC

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

o

6.

Citizenship or Place of Organization


Delaware, United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

61,542 shares of common stock (2)

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

61,542 shares of common stock (2)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

61,542 shares of common stock (2)

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

o

13.

Percent of Class Represented by Amount in Row 11

0.2% (3)

14.

Type of Reporting Person (see instructions)

 

PN

 


(1) This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) These shares are held by 5AM Co-Investors IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM Co-Investors IV.

(3) This calculation is based on  29,069,719 shares of Common Stock, par value $0.0001 per share, outstanding as of November 6, 2020, as reported in the 10-Q.

 

3


 

CUSIP No. 45166A 102

13D

 

 

1.

Name of Reporting Persons

 

5AM Partners IV, LLC

2.

Check the Appropriate Box if a Member of a Group (see instructions)

 

 

(a)

o

 

(b)

x(1)

3.

SEC USE ONLY

4.

Source of Funds (see instructions)

 

AF

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

o

6.

Citizenship or Place of Organization


Delaware, United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

1,545,970 shares of common stock (2)

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

1,545,970 shares of common stock (2)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,545,970 shares of common stock (2)

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

o

13.

Percent of Class Represented by Amount in Row 11

5.3% (3)

14.

Type of Reporting Person (see instructions)

 

OO

 


(1) This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) Includes (i) 1,477,028 shares held by 5AM IV; (ii) 61,542 shares held by 5AM Co-Investors IV; and (iii) 7,400 shares held by 5AM Partners IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV and 5AM Co-Investors IV.

(3) This calculation is based on  29,069,719 shares of Common Stock, par value $0.0001 per share, outstanding as of November 6, 2020, as reported in the 10-Q.

 

4


 

CUSIP No. 45166A 102

13D

 

 

1.

Name of Reporting Persons

 

5AM Opportunities I, L.P.

2.

Check the Appropriate Box if a Member of a Group (see instructions)

 

 

(a)

o

 

(b)

x(1)

3.

SEC USE ONLY

4.

Source of Funds (see instructions)

 

WC

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

o

6.

Citizenship or Place of Organization


Delaware, United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

259,496 shares of common stock (2) 

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

259,496 shares of common stock (2)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

259,496 shares of common stock (2)

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

o

13.

Percent of Class Represented by Amount in Row 11

0.9% (3)

14.

Type of Reporting Person (see instructions)

 

PN

 


(1) This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) These shares are held by 5AM Opportunities.  Schwab and Dr. Kush Parmar, as Managing Members of 5AM Opportunities GP, share voting and investment authority over the shares held by 5AM Opportunities.

(3) This calculation is based on  29,069,719 shares of Common Stock, par value $0.0001 per share, outstanding as of November 6, 2020, as reported in the 10-Q.

 

5


 

CUSIP No. 45166A 102

13D

 

 

1.

Name of Reporting Persons

 

5AM Opportunities I (GP), LLC

2.

Check the Appropriate Box if a Member of a Group (see instructions)

 

 

(a)

o

 

(b)

x(1)

3.

SEC USE ONLY

4.

Source of Funds (see instructions)

 

AF

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

o

6.

Citizenship or Place of Organization


Delaware, United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

260,746 shares of common stock (2)

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

260,746 shares of common stock (2)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

260,746 shares of common stock (2)

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

o

13.

Percent of Class Represented by Amount in Row 11

0.9% (3)

14.

Type of Reporting Person (see instructions)

 

OO

 


(1) This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) Includes 259,496 shares held by 5AM Opportunities and 1,250 shares held by 5AM Opportunities GP.  Schwab and Dr. Kush Parmar, as Managing Members of 5AM Opportunities GP, share voting and investment authority over the shares held by 5AM Opportunities.

(3) This calculation is based on  29,069,719 shares of Common Stock, par value $0.0001 per share, outstanding as of November 6, 2020, as reported in the 10-Q.

 

6


 

CUSIP No. 45166A 102

13D

 

 

1.

Name of Reporting Persons

 

Dr. John D. Diekman

2.

Check the Appropriate Box if a Member of a Group (see instructions)

 

 

(a)

o

 

(b)

x(1)

3.

SEC USE ONLY

4.

Source of Funds (see instructions)

 

AF

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

o

6.

Citizenship or Place of Organization


United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

1,545,970 shares of common stock (2)

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

1,545,970 shares of common stock (2)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,545,970 shares of common stock (2)

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

o

13.

Percent of Class Represented by Amount in Row 11

5.3% (3)

14.

Type of Reporting Person (see instructions)

 

IN

 


(1) This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) Includes (i) 1,477,028 shares held by 5AM IV; (ii) 61,542 shares held by 5AM Co-Investors IV; and (iii) 7,400 shares held by 5AM Partners IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV and 5AM Co-Investors IV.

(3) This calculation is based on  29,069,719 shares of Common Stock, par value $0.0001 per share, outstanding as of November 6, 2020, as reported in the 10-Q.

 

7


 

CUSIP No. 45166A 102

13D

 

 

1.

Name of Reporting Persons

 

Andrew J. Schwab

2.

Check the Appropriate Box if a Member of a Group (see instructions)

 

 

(a)

o

 

(b)

x(1)

3.

SEC USE ONLY

4.

Source of Funds (see instructions)

 

AF

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

o

6.

Citizenship or Place of Organization


United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

1,806,716 shares of common stock (2)

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

1,806,716 shares of common stock (2)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,806,716 shares of common stock (2)

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

o

13.

Percent of Class Represented by Amount in Row 11

6.2% (3)

14.

Type of Reporting Person (see instructions)

 

IN

 


(1) This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) Includes (i) 1,477,028 shares held by 5AM IV; (ii) 61,542 shares held by 5AM Co-Investors IV; (iii) 7,400 shares held by 5AM Partners IV; (iv) 259,496 shares held by 5AM Opportunities; and (v) 1,250 shares held by 5AM Opportunities GP.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV and 5AM Co-Investors IV.  Schwab and Dr. Kush Parmar, as Managing Members of 5AM Opportunities GP, share voting and investment authority over the shares held by 5AM Opportunities.

(3) This calculation is based on  29,069,719 shares of Common Stock, par value $0.0001 per share, outstanding as of November 6, 2020, as reported in the 10-Q.

 

8


 

CUSIP No. 45166A 102

13D

 

 

1.

Name of Reporting Persons

 

Dr. Scott M. Rocklage

2.

Check the Appropriate Box if a Member of a Group (see instructions)

 

 

(a)

o

 

(b)

x(1)

3.

SEC USE ONLY

4.

Source of Funds (see instructions)

 

AF

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

o

6.

Citizenship or Place of Organization


United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

1,545,970 shares of common stock (2)

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

1,545,970 shares of common stock (2)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,545,970 shares of common stock (2)

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

o

13.

Percent of Class Represented by Amount in Row 11

5.3% (3)

14.

Type of Reporting Person (see instructions)

 

IN

 


(1) This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) Includes (i) 1,477,028 shares held by 5AM IV; (ii) 61,542 shares held by 5AM Co-Investors IV; and (iii) 7,400 shares held by 5AM Partners IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV and 5AM Co-Investors IV.

(3) This calculation is based on 29,069,719 shares of Common Stock, par value $0.0001 per share, outstanding as of November 6, 2020, as reported in the 10-Q.

 

9


 

CUSIP No. 45166A 102

13D

 

 

Explanatory Note:    This Amendment No. 2 (the “Amendment”), which further amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on June 10, 2019 and amended on November 16, 2020 (as amended, the “Original Schedule 13D”) is being filed on behalf of 5AM Partners IV, LLC (“5AM Partners IV”), 5AM Ventures IV, L.P. (“5AM IV”), 5AM Co-Investors IV, L.P. (“5AM Co-Investors IV”), 5AM Opportunities I, L.P. (“5AM Opportunities”), 5AM Opportunities I (GP), LLC (“5AM Opportunities GP”),  Dr. John D. Diekman (“Diekman”), Andrew J. Schwab (“Schwab”) and Dr. Scott M. Rocklage (“Rocklage” and, with 5AM Partners IV, 5AM IV, 5AM Co-Investors IV, 5AM Opportunities, 5AM Opportunities GP, Diekman and Schwab, collectively, the “Reporting Persons”) in respect of the Common Stock, $0.0001 par value per share (“Common Stock”), of IDEAYA Biosciences, Inc., a Delaware corporation (the “Issuer” or “IDEAYA”). This Amendment is being filed by the Reporting Persons to report distribution of Common Stock on December 10, 2020.  Accordingly, the number of securities beneficially owned by the Reporting Persons has decreased as described in Items 4 and 5 below.

 

Items 4 and 5 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect.  All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

 

Item 4.   Purpose of Transaction

 

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 4:

 

On December 10, 2020, 5AM IV made a pro rata in-kind distribution for no additional consideration of 710,400 shares of Common Stock to its general partner, 5AM Partners IV, LLC, and its limited partners.  On December 10, 2020, 5AM Co-Investors IV made a pro rata in-kind distribution for no additional consideration of 29,600 shares of Common Stock to its general partner, 5AM Partners IV, LLC, and its limited partners.  Of the shares distributed by 5AM IV and 5AM Co-Investors IV, 5AM Partners IV, LLC received an aggregate of 7,400 shares.  On December 10, 2020, 5AM Opportunities made a pro rata in-kind distribution for no additional consideration of 125,000 shares of Common Stock to its general partner, 5AM Opportunities GP, and its limited partners. Of the shares distributed by 5AM Opportunities, 5AM Opportunities GP received 1,250 shares.

 

10


 

CUSIP No. 45166A 102

13D

 

 

Item 5.   Interest in Securities of the Issuer

 

Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

 

(a) — (b). The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of December 14, 2020:

 

Reporting Persons

 

Shares Held
Directly

 

Sole Voting
Power

 

Shared
Voting
Power(1)

 

Sole
Dispositive
Power

 

Shared
Dispositive
Power (1)

 

Beneficial
Ownership

 

Percentage
of Class (3)

 

5AM IV

 

1,477,028

 

0

 

1,477,028

 

0

 

1,477,028

 

1,477,028

 

5.1

%

5AM Co-Investors IV

 

61,542

 

0

 

61,542

 

0

 

61,542

 

61,542

 

0.2

%

5AM Partners IV (1)

 

7,400

 

0

 

1,545,970

 

0

 

1,545,970

 

1,545,970

 

5.3

%

5AM Opportunities

 

259,496

 

0

 

259,496

 

0

 

259,496

 

259,496

 

0.9

%

5AM Opportunities GP (2)

 

1,250

 

0

 

260,746

 

0

 

260,746

 

260,746

 

0.9

%

Diekman (1)

 

0

 

0

 

1,545,970

 

0

 

1,545,970

 

1,545,970

 

5.3

%

Schwab (1) (2)

 

0

 

0

 

1,806,716

 

0

 

1,806,716

 

1,806,716

 

6.2

%

Rocklage (1) 

 

0

 

0

 

1,545,970

 

0

 

1,545,970

 

1,545,970

 

5.3

%

 


(1)         Includes (i) 1,477,028 shares held by 5AM IV; (ii) 61,542 shares held by 5AM Co-Investors IV; and (iii) 7,400 shares held by 5AM Partners IV.  Diekman, Schwab and Rocklage, as managing members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV and 5AM Co-Investors IV.

(2)         Includes 259,496 shares held by 5AM Opportunities and 1,250 shares held by 5AM Opportunities GP.  Schwab and Parmar, as managing members of 5AM Opportunities GP, share voting and investment authority over the shares held by 5AM Opportunities.

(3)         This calculation is based on 29,069,719 shares of Common Stock, par value $0.0001 per share, outstanding as of November 6, 2020, as reported in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2020 (the “10-Q”) filed on November 12, 2020 with the SEC.

 

(c)    Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer’s Common Stock since November 13, 2020, the date as of which beneficial ownership information was presented in the most recent amendment to this Schedule 13D.

 

(d)    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

 

(e)     Not applicable.

 

11


 

CUSIP No. 45166A 102

13D

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date:  December 14, 2020

 

 

5AM Ventures IV, L.P.

 

 

 

 

By:

5AM Partners IV, LLC,

 

 

Its General Partner

 

 

 

 

 

 

 

By:

/s/ Andrew J. Schwab

 

 

Andrew J. Schwab

 

 

Managing Member< /font>

 

 

 

 

 

 

 

5AM Co-Investors IV, L.P.

 

 

 

 

By:

5AM Partners IV, LLC,

 

 

Its General Partner

 

 

 

 

 

 

 

By:

/s/ Andrew J. Schwab

 

 

Andrew J. Schwab

 

 

Managing Member

 

 

 

 

 

 

 

5AM Partners IV, LLC

 

 

 

 

 

 

By:

/s/ Andrew J. Schwab

 

 

Andrew J. Schwab

 

 

Managing Member

 

 

 

 

 

 

 

5AM Opportunities I, L.P.

 

 

 

 

By:

5AM Opportunities I (GP), LLC,

 

 

Its General Partner

 

 

 

 

 

 

 

By:

/s/ Dr. Kush M. Parmar

 

 

Dr. Kush M. Parmar

 

 

Managing Member

 

 

 

 

 

 

 

5AM Opportunities I (GP), LLC

 

 

 

 

 

 

By:

/s/ Dr. Kush M. Parmar

 

 

Dr. Kush M. Parmar

 

 

Managing Member

 

 

 

 

 

 

 

DR. JOHN D. DIEKMAN

 

 

 

 

 

 

By:

/s/ Dr. John D. Diekman

 

 

Dr. John D. Diekman

 

12


 

CUSIP No. 45166A 102

13D

 

 

 

ANDREW J. SCHWAB

 

 

 

 

 

By:

/s/ Andrew J. Schwab

 

 

Andrew J. Schwab

 

 

 

 

 

 

 

DR. SCOTT M. ROCKLAGE

 

 

 

 

 

 

 

By:

/s/ Dr. Scott M. Rocklage

 

 

Dr. Scott M. Rocklage

 

13